Comparative Pharmacology
Head-to-head clinical analysis: CEFTIN versus MAXIPIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTIN versus MAXIPIME.
CEFTIN vs MAXIPIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftin (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically transpeptidases, thereby disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily during active cell division.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It has enhanced activity against Gram-negative bacteria due to rapid penetration through the outer membrane and low affinity for β-lactamases.
250-500 mg orally twice daily for 10 days; for community-acquired pneumonia, 500 mg twice daily for 10 days. Intravenous: 750-1500 mg every 8 hours.
1-2 g IV every 8-12 hours for most indications; maximum 2 g every 8 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (normal renal function); prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 2-2.5 hours in adults with normal renal function; extends to 8-12 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 20-24 hours in severe impairment (CrCl < 30 mL/min).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal (approximately 80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion is minimal (< 1%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic